Eden Research Plc offers sustainable solutions for crop protection, animal health and consumer products in the United Kingdom and rest of Europe. The company is headquartered in Oxford, Oxfordshire and currently employs 23 full-time employees. The company went IPO on 2012-05-11. The firm develops and supplies biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries. Its products include crop protection, animal health, and consumer products. Its crop protection includes Mevalone and Cedroz. Mevalone is a foliar, contact biofungicide which delivers a controlled release pattern of multiple terpene active ingredients. Cedroz is a terpene-based product developed in conjunction with Eastman Chemical Company as a post-planting solution to the problem of root-knot nematodes. The firm's Sustaine encapsulation technology is used to harness the biocidal activity of naturally occurring molecules produced by plants (terpenes) as part of their defence systems. Sustaine is used in a wide range of applications such as agricultural, animal health and consumer products
根據最新的財務報表(Form-10K),Babcock International Group PLC 的總資產為 $0,淨isProfitable}為 $0
EDNSF 的關鍵財務比率是什麼?
Babcock International Group PLC 的流動比率為 0,淨利潤率為 0,每股銷售為 $0。
Eden Research plc 的收入按細分市場或地理位置如何劃分?
Babcock International Group PLC 最大收入來源為 Nuclear,在最近的收益報告中收入為 1,816,000,000。就地區而言,United Kingdom 是 Babcock International Group PLC 的主要市場,收入為 3,448,300,000。
Eden Research plc 是否盈利?
無,根據最新的財務報表,Babcock International Group PLC 的淨損失為 $0